title: Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy.
abstract: Inborn errors of catecholamine biosynthesis are rare but of great interest as they are genetic disorders, and in some, treatment may completely reverse severe neurological abnormalities. They also provide insights into the action of the biogenic amines in the developing brain. We describe the clinical course of an infant with tyrosine hydroxylase (TOH) deficiency over a 30-month period. The parents are consanguineous, and genetic analysis revealed the infant to be homozygous for the common G698A mutation in the TOH gene. TOH deficiency can be seen as a model of pure catecholamine deficiency. Experimental evidence, reports of other disorders of biogenic amines, and our experience with this infant suggest that the symptoms of catecholamine deficiency in infancy can be broadly subdivided. Signs of dopamine deficiency include tremor, hypersensitivity to levadopa (L-dopa) therapy, oculogyric crises, akinesia, rigidity, and dystonia. Manifestations of norepinephrine deficiency include ptosis, miosis, profuse oropharyngeal secretions, and postural hypotension. Hypersensitivity to L-dopa was a particular management problem in this infant.
authors.affiliation: Department of Neurology, Royal Alexandra Hospital for Children Westmead, Sydney, Australia. Grattan-SmithP@sesahs.nsw.gov.au
authors.forename: Padraic J
authors.initials: PJ
authors.lastname: Grattan-Smith
authors.forename: Ron A
authors.initials: RA
authors.lastname: Wevers
authors.forename: Gerry C
authors.initials: GC
authors.lastname: Steenbergen-Spanjers
authors.forename: Victor S C
authors.initials: VS
authors.lastname: Fung
authors.forename: John
authors.initials: J
authors.lastname: Earl
authors.forename: Bridget
authors.initials: B
authors.lastname: Wilcken
mesh_terms: D003241:Consanguinity; D002658:Developmental Disabilities / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D004298:Dopamine / Q000172:deficiency* / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D009460:Neurologic Examination / Q000187:drug effects; D009638:Norepinephrine / Q000172:deficiency* / Q000235:genetics; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D014202:Tremor / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D014446:Tyrosine 3-Monooxygenase / Q000172:deficiency* / Q000235:genetics
chemical_list: D007980:Levodopa; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D009638:Norepinephrine